TY - JOUR
KW - buprenorphine
KW - Buprenorphine/therapeutic use
KW - Focus Groups
KW - Humans
KW - Narcotic Antagonists/therapeutic use
KW - office visits
KW - opiate addiction
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy
KW - Patient Preference
KW - Primary Health Care
KW - psychosocial support
KW - Qualitative Research
KW - Social Support
AU - A. D. Fox
AU - M. Masyukova
AU - C. O. Cunningham
A1 - 
AB - BACKGROUND: Buprenorphine maintenance treatment is effective and has been successfully integrated into human immunodeficiency virus (HIV) and primary care settings. However, one key barrier to providers prescribing buprenorphine is their perception that they are unable to provide adequate counseling or psychosocial support to patients with opioid addiction. This qualitative study investigated supportive elements of office-based buprenorphine treatment that patients perceived to be most valuable. METHODS: The authors conducted five focus groups with 33 buprenorphine treatment-experienced participants. Focus groups were audio-recorded and transcribed. Iterative readings of transcripts and grounded theory analysis revealed common themes. RESULTS: Overall, participants perceived that buprenorphine treatment helped them to achieve their treatment goals and valued the flexibility, accessibility, and privacy of treatment. Participants identified interpersonal and structural elements of buprenorphine treatment that provided psychosocial support. Participants desired good physician-patient relationships, but also valued care delivery models that were patient-centered, created a safe place for self-disclosure, and utilized coordinated team-based care. CONCLUSIONS: Participants derived psychosocial support from their prescribing physician, but were also open to collaborative or team-based models of care, as long as they were voluntary and confidential. Buprenorphine-prescribing physicians without access to referral options for psychosocial counseling could focus on maintaining nonjudgmental attitudes and shared decision-making during patient encounters. Adding structure and psychosocial support to buprenorphine treatment through coordinated team-based care also seems to have great promise.
BT - Substance abuse
C5 - Opioids & Substance Use
CP - 1
CY - United States
DO - 10.1080/08897077.2015.1088496
IS - 1
JF - Substance abuse
N2 - BACKGROUND: Buprenorphine maintenance treatment is effective and has been successfully integrated into human immunodeficiency virus (HIV) and primary care settings. However, one key barrier to providers prescribing buprenorphine is their perception that they are unable to provide adequate counseling or psychosocial support to patients with opioid addiction. This qualitative study investigated supportive elements of office-based buprenorphine treatment that patients perceived to be most valuable. METHODS: The authors conducted five focus groups with 33 buprenorphine treatment-experienced participants. Focus groups were audio-recorded and transcribed. Iterative readings of transcripts and grounded theory analysis revealed common themes. RESULTS: Overall, participants perceived that buprenorphine treatment helped them to achieve their treatment goals and valued the flexibility, accessibility, and privacy of treatment. Participants identified interpersonal and structural elements of buprenorphine treatment that provided psychosocial support. Participants desired good physician-patient relationships, but also valued care delivery models that were patient-centered, created a safe place for self-disclosure, and utilized coordinated team-based care. CONCLUSIONS: Participants derived psychosocial support from their prescribing physician, but were also open to collaborative or team-based models of care, as long as they were voluntary and confidential. Buprenorphine-prescribing physicians without access to referral options for psychosocial counseling could focus on maintaining nonjudgmental attitudes and shared decision-making during patient encounters. Adding structure and psychosocial support to buprenorphine treatment through coordinated team-based care also seems to have great promise.
PP - United States
PY - 2016
SN - 1547-0164; 0889-7077
SP - 70
EP - 75
EP - 
T1 - Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients' experiences and preferences
T2 - Substance abuse
TI - Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients' experiences and preferences
U1 - Opioids & Substance Use
U2 - 26566712
U3 - 10.1080/08897077.2015.1088496
VL - 37
VO - 1547-0164; 0889-7077
Y1 - 2016
ER -